NR3C2 and chronic kidney disease: Over the past few years, new pharmacotherapeutic options to slow progression of CKD have emerged, including sodium-glucose cotransporter 2 (SGLT2) inhibitors and the mineralocorticoid receptor antagonist finerenone.1 Despite these new evidence-based therapies, a significant proportion of patients with CKD continue to have elevated albuminuria, which is associated with a persistently higher risk of progressive kidney function loss and cardiovascular complications.2